Research Round Up Podcasts: Genitourinary and Gastrointestinal Cancers

Research Round Up Podcast Series
July 28, 2016
Claire Smith, ASCO staff

The field of immunotherapy has been named the most significant cancer advance of 2016, so it’s no surprise that at the 2016 ASCO Annual Meeting, there was widespread research in this area. With certain types of cancer, such as advanced bladder cancer, these new therapies represent the first major advances in many years.

In the following 2 Research Round Up podcasts, Cancer.Net Associate Editors Brian Rini, MD, and Jeffrey Meyerhardt, MD, MPH, discuss new research across a wide range of genitourinary and gastrointestinal cancers and explain what this research means for people with cancer.

New immunotherapy and targeted treatments for advanced bladder and kidney cancer

Dr. Rini from the Cleveland Clinic Taussig Cancer Institute discusses new advances in advanced bladder cancer and advanced kidney cancer: share on Twitter

  • The FDA recently approved a PD-L1 inhibitor, atezolizumab (Tecentriq), to treat advanced bladder cancer for certain patients. New research suggests additional uses for this drug, particularly for people with advanced bladder cancer who are not able to receive current standard treatment [1:23].

  • Other immunotherapy drugs, such as durvalumab and nivolumab (Opdivo), also show early promise in treating advanced bladder cancer [4:20].

  • Updated research on a targeted therapy called cabozantinib (Cabometyx, Cometriq) for advanced kidney cancer shows an increase in overall survival compared with standard treatment [5:38].

  • New long-term data on nivolumab for advanced kidney cancer shows that many patients have had good results even after several years [7:40].

Read a full transcript of this podcast.

New and ongoing research in colorectal, pancreatic, and stomach cancers

Dr. Meyerhardt from the Dana-Farber Cancer Institute discusses new advances in colorectal cancer, pancreatic cancer, and stomach cancer: share on Twitter 

  • Research indicates that there might be biological differences between tumors that start on the right or the left side of the colon, which could help when making decisions about treatment [1:31].

  • One early study suggests that a combination of 2 immunotherapy drugs, nivolumab and ipilimumab (Yervoy), slows or stops the growth of metastatic microsatellite-instable or “MSI-high” colorectal tumors, which are often related to Lynch syndrome [5:26].

  • Another study shows that a combination of 2 different immunotherapy drugs, atezolizumab and cobimetinib (Cotellic) may be effective in treating microsatellite-stable colorectal cancer, although more research is needed [10:22].

  • New research explored different options for adjuvant therapy for people with pancreatic and stomach cancer. Adjuvant therapy is treatment, such as chemotherapy or radiation therapy, that is given after surgery [12:50].

  • An antibody targeting a specific protein could significantly lengthen the lives of people with stomach cancer that has high levels of this protein [18:47].

Read a full transcript of this podcast.

These are prerecorded audio podcasts. They can be listened to online or downloaded to your computer. For more information, visit the Cancer.Net podcast page.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.